Abrocitinib is indicated for:
Population group: both men and women, only adults (18 - 65 years old)
Abrocitinib is indicated for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Abrocitinib is contraindicated in the following cases: